Cancer Mortality of Thorotrast Patients in Japan: The Second Series Updated 1998

Kido, C; Sasaki, Fumio; Hirota, Yutaka; Kiyosawa, K; Hayashi, Shuhei; Mori, Takesaburo; Sobue, Tomotaka

doi:10.2307/3580119

Cited by 7 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…excluding environmental exposure studies. Two types of studies were identified as suitable: Follow-up studies of patients who received the 232 Th-containing X-ray contrast medium Thorotrast (5)(6)(7)(8)(9) and patients who received 224 Ra for the treatment of tuberculosis and ankylosing spondylitis (10)(11)(12). In all, six Thorotrast series (Table 1) and two 224 Ra-studies (Table 2) were identified.…”

Section: Background Datamentioning

confidence: 99%

“…By directly calculating risk following alpha irradiation from the known long-term effects of other alpha irradiations, the uncertainty involved in determining a radiation weighting factor for alpha irradiation is eliminated. Published organ-by-organ relative risks for secondary cancer following administration of alpha-emitting compounds Thorotrast (5)(6)(7)(8)(9) and 224 Ra (10)(11)(12) were used.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy

et al. 2022

View full text Add to dashboard Cite

Intraperitoneal 211 At-based targeted alpha therapy (TAT) may hold most promise as an adjuvant therapy following surgery and chemotherapy in epithelial ovarian cancer to eradicate any remaining undetectable disease. This implies it will also be delivered to patients possibly already cured by the primary treatment. An estimate of long-term risks is therefore sought whether to justify the treatment. Methods: Baseline data for risk estimates of alpha-particle irradiation were collected from published studies on excess cancer induction and mortality for subjects exposed to either 224 Ra treatments or Thorotrast contrast agent (25% ThO2 colloid, containing 232 Th). Organ dosimetry for 224 Ra and Thorotrast irradiation were taken from the literature. These organ-specific risks were then applied for our previously reported dosimetry for intraperitoneal (i.p.) 211 At-TAT patients. Results: Risk could be estimated for 10 different organ or organ groups. The calculated excess relative risk per Gray (ERR/Gy) could be sorted into two groups. In the lower ERR/Gy group, up to approx. 5, were: Trachea, bronchus and lung 0.52 (CI 95% 0.21-0.82), Stomach 1.4 (CI 95% -5.0-7.9), Lymphoid and hematopoietic system 2.17 (CI 95% 1.7-2.7), Bone and articular cartilage 2.6 (CI 95% 2.0-3.3), Breast 3.45 (CI 95% -10-17) and Colon 4.5 (CI 95% -3.5-13). In the higher ERR/Gy group, ranging from approx. 10 to 15 were:

show abstract

Section: Background Datamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thorotrast-exposed patients are the fourth largest human population significantly exposed to an alpha-emitting heavy metal (Stannard 1988) and have been studied internationally. Research was conducted by others to verify the Advisory Committee statement using the latest available data from Danish (Andersson and Storm 1992;Andersson et al 1994; Advisory Committee on Radiological Protection 1996), German (van Kaick et al 1984;van Kaick et al 1999), Japanese (Kido et al 1999;Mori et al 1999a;Mori et al 1999b), Portuguese (dos Santos-Silva et al 1999, and Swedish (Martling et al 1999) studies. We conclude that the apparent threshold may be an artifact of the assumed 15-year latency period for Thorotrast-initiated liver cancer, and that the significant, possibly causal, dose accumulates over a latency period (even for minimal Thorotrast administrations).…”

Section: Human Thorium Exposure and Liver Cancermentioning

confidence: 99%

Laboratory Directed Research and Development Annual Report - Fiscal Year 2000

Fisher¹,

Hughes²,

Pearson³

2001

View full text Add to dashboard Cite

I am pleased to present the FY 2000 Annual Report on Laboratory Directed Research and Development (LDRD) at the Pacific Northwest National Laboratory. From our LDRD program springs a renewed vitality of science and technology, a test bed for promising research, and most importantly, a strengthened ability to address complex problems of national importance.The LDRD program provides an opportunity for our staff to conduct experimental research on advanced scientific areas that have the potential for important new discoveries and innovative solutions to difficult technical problems. These projects span a broad range of topics-from subsurface microbes to atmospheric processes, and from nanoscale atom clusters to geologic oil reserves.Perhaps one of the most exciting LDRD projects described in this year's report is one in the life sciences where we have extended previous work in genomics into the new frontier area of proteomics. Using mass spectrometry to catalogue and characterize proteins on a large scale, we can now rapidly identify proteins that are made in response to a change in the cellular environment. Many of these proteins have never been described. This advance in fundamental biology could greatly improve our understanding of how cells respond to toxic insults and could lead to new techniques for bioremediation and environmental cleanup as well as early diagnosis and treatment of diseases.As we head into the next century, we will be relying on the LDRD program to form the foundation for a new generation of products and processes that will benefit the U.S. Department of Energy, the nation, and the taxpayers. For example, LDRD-funded research on fuel cells promises to yield important new advances in powering energy-efficient, low-polluting automobiles and trucks. The increasing importance of computer information and network security also is being addressed through LDRD research, where we are developing technologies that could prevent destructive intrusions on national energy, transportation, and communication centers.Keeping us at the cutting edge of science and technology, the LDRD program fosters an innovative work environment that helps us recruit and retain the best and brightest staff. Here, our scientists and engineers are encouraged to turn their discoveries into practical solutions.The LDRD program has proven essential to the outstanding record of achievement at Pacific Northwest National Laboratory, and we expect it to remain a cornerstone of our success in the 21 st century.

show abstract

Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study

Becker

Liebermann

Wesch

et al. 2008

European Journal of Cancer

View full text Add to dashboard Cite

Cancer Mortality of Thorotrast Patients in Japan: The Second Series Updated 1998

Cited by 7 publications

References 2 publications

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy

Laboratory Directed Research and Development Annual Report - Fiscal Year 2000

Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study

Contact Info

Product

Resources

About

Cancer Mortality of Thorotrast Patients in Japan: The Second Series Updated 1998

Cited by 7 publications

References 2 publications

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy

Laboratory Directed Research and Development Annual Report - Fiscal Year 2000

Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study

Contact Info

Product

Resources

About

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy